Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Review article: emerging drug therapies in inflammatory bowel disease
Laurie B. Grossberg, Konstantinos Papamichael, Adam S. Cheifetz
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 7, pp. 789-804
Closed Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease
Defeng Li, Meifeng Yang, Haoming Xu, et al.
Journal of Materials Chemistry B (2022) Vol. 10, Iss. 31, pp. 5853-5872
Closed Access | Times Cited: 56
Gegen Qinlian decoction activates AhR/IL-22 to repair intestinal barrier by modulating gut microbiota-related tryptophan metabolism in ulcerative colitis mice
Xiaojing Wang, Shaowei Huang, Meiling Zhang, et al.
Journal of Ethnopharmacology (2022) Vol. 302, pp. 115919-115919
Closed Access | Times Cited: 51
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
William J. Sandborn, Julián Panés, Silvio Danese, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 43-55
Closed Access | Times Cited: 40
Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy
Olga Maria Nardone, Irene Zammarchi, Giovanni Santacroce, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2389-2389
Open Access | Times Cited: 30
Advancements in Inflammatory Bowel Disease: A Narrative Review of Diagnostics, Management, Epidemiology, Prevalence, Patient Outcomes, Quality of Life, and Clinical Presentation
Muhammad Ali Muzammil, Fnu Fariha, Tirath Patel, et al.
Cureus (2023)
Open Access | Times Cited: 28
Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Virginia Solitano, Sudheer K. Vuyyuru, John K MacDonald, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 11, pp. 1800-1816
Closed Access | Times Cited: 24
A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis
Marek Vébr, Renata Pomahačová, Josef Sýkora, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3229-3229
Open Access | Times Cited: 24
Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery
Kat F. Kiilerich, Trine Andresen, Behrooz Darbani, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 575-575
Open Access | Times Cited: 1
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1231-1248
Open Access | Times Cited: 20
Gut-licensed β7 + CD4 + T cells contribute to progressive retinal ganglion cell damage in glaucoma
Chong He, Wenbo Xiu, Qinyuan Chen, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 707
Closed Access | Times Cited: 19
pH-Sensitive Hydrogels Fabricated with Hyaluronic Acid as a Polymer for Site-Specific Delivery of Mesalamine
Huma Liaqat, Syed Faisal Badshah, Muhammad Usman Minhas, et al.
ACS Omega (2024) Vol. 9, Iss. 26, pp. 28827-28840
Open Access | Times Cited: 5
Esophageal lichen planus: Current knowledge, challenges and future perspectives
Annegrit Decker, Franziska Schauer, Adhara Lazaro, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 41, pp. 5893-5909
Open Access | Times Cited: 19
Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
Yihan Xu, Weiming Zhu, Zhen Guo
World Journal of Gastroenterology (2022) Vol. 28, Iss. 48, pp. 6888-6899
Open Access | Times Cited: 19
Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes
Sara Horst, Raymond Cross
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 273-282
Open Access | Times Cited: 11
Paeonol alleviates ulcerative colitis in mice by increasing short-chain fatty acids derived from Clostridium butyricum
Meng Zhao, Xueqian Xie, Bo Xu, et al.
Phytomedicine (2023) Vol. 120, pp. 155056-155056
Closed Access | Times Cited: 11
Exploring Chemoprevention in Colorectal Cancer for Patients with Inflammatory Bowel Disease: Mechanisms of Action and Clinical Aspects
Fotios S. Fousekis, Konstantinos Mpakogiannis, Panagiotis Filis, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 229-229
Open Access
Exploring the potential mechanism of B-phycoerythrin on DSS-induced colitis and colitis-associated bone loss based on network pharmacology, molecular docking, and experimental validation
Lu-Ming Deng, Feng Zhang, Xingyan Li, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Treatment sequencing in inflammatory bowel disease : towards clinical precision medicine
Léa Sequier, Bénédicte Caron, Sailish Honap, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101994-101994
Closed Access
Age and Socioeconomic Deprivation as Key Predictors of Cardiovascular Risk in Patients With Autoimmune Rheumatic Diseases on JAK Inhibitors
Kehinde Sunmboye, B Nguyen Bui
International Journal of Rheumatic Diseases (2025) Vol. 28, Iss. 3
Closed Access
Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease
Zonghui Ma, Steven McAninch, Zhiqing Liu, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 4, pp. 1152-1167
Closed Access
S1PR4-dependent effects of Etrasimod on primary human myeloid immune cell activation
Fiona Sailer, Megan A. Palmer, Blerina Aliraj, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application
Jiayi Jin, Lijun Yue, Maoru Du, et al.
MedComm (2025) Vol. 6, Iss. 5
Open Access
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease
Francesca Lusetti, Ferdinando D’Amico, Mariangela Allocca, et al.
Immunotherapy (2024) Vol. 16, Iss. 9, pp. 581-595
Closed Access | Times Cited: 3
SIRT3 Activator Honokiol Inhibits Th17 Cell Differentiation and Alleviates Colitis
Xiaotian Chen, Mingming Zhang, Fan Zhou, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 12, pp. 1929-1940
Open Access | Times Cited: 9
The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease
Jacopo Fanizza, Ferdinando D’Amico, Gaetano Lauri, et al.
Immunotherapy (2023) Vol. 16, Iss. 2, pp. 59-74
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top